Abstract
Abstract In the present study, we examined the effect of bexarotene (Targretin) and budesonide in chemoprevention of small cell lung carcinoma (mSCLC) using a lung specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (p < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (p > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/p53 gene targeted mouse appears to be a valuable model for chemopreventive studies on human small cell lung cancer (hSCLC). Our results indicate that the retinoid X receptor (RXR) agonist bexarotene may be a potent chemopreventive agent in this cancer type. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A92.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
